<DOC>
	<DOC>NCT02731885</DOC>
	<brief_summary>The goal of this study is to determine the impact of the food on the absorption of the ABX464.</brief_summary>
	<brief_title>Food Effect on Pharmacokinetic Parameters of ABX464</brief_title>
	<detailed_description>This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464. The two different treatments are the followings: - Treatment A = 50mg of ABX464 (two 25mg capsules) /Fasted - Treatment B = 50mg of ABX464 (two 25mg capsules) / Fed This study consists of two groups: - Group 1 - single dose assessments, two-period, two-treatment, cross-over: 20 subjects will receive a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days. - Group 2 - multiple dose assessments: 20 subjects will receive 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.</detailed_description>
	<criteria>Healthy Caucasian male subjects, 1855 years of age Body Mass Index (BMI) of 1728 kg/mÂ². Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) Normal vital signs after 10 minutes resting in supine position: 90 mmHg &lt; systolic blood pressure &lt; 140 mmHg, 50 mmHg &lt; diastolic blood pressure &lt; 90 mmHg, 40 bpm &lt; heart rate &lt; 100 bpm. Normal automatic 12lead ECG (incomplete right bundle branch block can be accepted) or judged as non clinically significant. Clinical laboratory tests (hematology, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to Investigator and Sponsor. Subjects must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules. Individuals with a history of any significant medical disorder which requires a physician's care (cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease; any acute infectious disease or signs of acute illness) Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month). Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician. Individuals who have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to drug administration. Any individual who does not comply with the requirement that he should not have used any drugs other than paracetamol for at least 2 weeks prior to the study nor alcohol within 48 hours prior to drug administration. Individuals who are positive for hepatitis B virus, hepatitis C virus or HIV. History or presence of drug or alcohol abuse (positive urine drug screen, positive alcohol breath test). Smoking more than 5 cigarettes or equivalent / day, unable to stop smoking during the study. Excessive consumption of beverages with xanthine bases (&gt; 4 cups or glasses / day). Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time. Individuals who have donated blood within the preceding 3 months. Individuals who refuse to use an effective method of contraception from the beginning of the study and until 3 months after dosing. Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>